Pfizer’s Covid vaccine could be rolled out to babies as young as six months in the US this winter, under plans being drawn up by the pharmaceutical giant. In a move likely to cause international controversy, the company intends to apply for authorization to immunize American infants within the next two months.
The Daily Mail reported that the timeline will depend on the findings of in-house trials looking into whether the vaccines are safe and effective in youngsters aged six months to five years. Frank D’Amelio, chief financial officer at Pfizer, told an industry conference yesterday that the firm plans to ‘go file’ by November, the Financial Times reports.
‘We would expect to have… data for children between the ages of six months and five years old that we would file with the FDA,’ D’Amelio said at the Morgan Stanley Global Healthcare Conference. ‘I’ll call it in the weeks shortly thereafter the filing of the data for the five- to 11-year-olds.’
Politico reported that Pfizer had previously flagged that it planned to apply for U.S. approval for the jab for children between the ages of 5 and 11 in early October. Speaking at the Morgan Stanley Global Healthcare Conference, D’Amelio said the application for children aged between 6 months and 5 years would be filed “in the weeks shortly thereafter the filing of the data for the 5 to the 11 year-olds … assuming all of the data is positive,” according to Pfizer’s transcript of his comments.